London is flying in the age of AI. Nearly 50% of all European VC is flowing into the UK.

Here are the companies that I would join if I was looking for a job today.

Top 15:

1. Ineffable Intelligence — $1.1bn seed (Apr 2026; co-led by Sequoia and Lightspeed, with Nvidia and Google) at $5.1bn — Europe's largest-ever seed; DeepMind's David Silver building AI that learns from experience toward "superintelligence".

2. Recursive Superintelligence — $650M (May 2026; led by GV and Greycroft, with AMD and Nvidia) at $4.65bn; self-improving AI that automates the research loop (SF + London).

3. ElevenLabs — $500M Series D (Feb 2026, led by Sequoia; a16z, ICONIQ) at $11bn; market-leading voice/audio AI.

4. Synthesia — ~$200M Series E (Jan 2026, led by Google Ventures) at $4bn; AI-avatar video generation for enterprise.

5. Nscale — $2bn Series C (Mar 2026; Nvidia, Nokia, Dell, Aker) after a $1.1bn Series B; AI datacentre and GPU-compute infrastructure. The extended list

6. PolyAI — $86M Series D (Dec 2025; Georgian, Hedosophia, Khosla); enterprise voice assistants for customer service.

7. Taktile — $110M Series C (Jun 2026; Goldman Sachs Growth, Index, Balderton); AI decisioning for financial institutions.

8. Granola ‹smaller› — $43M Series B (May 2025; NFDG — Nat Friedman & Daniel Gross), ~$70M total; AI meeting notepad/assistant.

9. Geordie AI ‹smaller› — $30M Series A (May 2026; Balderton, Crosspoint); security and governance for autonomous AI agents.

10. Cera — $150M round (Jan 2025; Schroders Capital, BDT & MSD) at $1bn+; AI-driven home healthcare.

11. Zango AI ‹smaller› — €4M (Jul 2025); AI agents for financial-services regulatory compliance.

12. Genie AI ‹smaller› — $18M (2025; GV-backed); AI legal drafting/contract tools used by a large self-serve base.

13. Tessl — $125M Series A (Nov 2024; Index, GV, Accel) at $500m+; "AI-native" software that writes and maintains code.

14. Unitary ‹smaller› — ~$15M Series A (2023; Creandum, Paladin); contextual AI for video content moderation.

15. Causaly — $60M Series B (Jul 2023, led by ICONIQ Growth); AI for biomedical research and drug-discovery evidence.